Spatial Distribution and Stability of Cholinesterase Inhibitory Protoberberine Alkaloids from Papaver setiferum

• Published in: Journal of natural products (Washington, D.C.) D.C.), 2022-01, Vol.85 (1), p.215-224
• Main Authors: Safa, Neda, Trobec, Tomaž, Holland, Darren C, Slazak, Blazej, Jacobsson, Erik, Hawkes, Jeffrey A, Frangež, Robert, Sepčić, Kristina, Göransson, Ulf, Moodie, Lindon W. K, Robertson, Luke P
• Format: Article
• Language: English
• Subjects: Animals; Berberine Alkaloids - chemistry; Berberine Alkaloids - pharmacology; Cholinesterase Inhibitors - pharmacology; Humans; Papaver - chemistry; Spectrometry, Mass, Electrospray Ionization
• ISSN: 0163-3864; 1520-6025; 1520-6025
• DOI: 10.1021/acs.jnatprod.1c00980

During a research program to identify new cholinesterase inhibitors of natural origin, two new 7,8-didehydroprotoberberine alkaloids (1 and 2) and nine known compounds (3–11) were isolated from the capsules of the common ornamental poppy, Papaver setiferum (previously P. pseudo-orientale). Despite their reported instability, the 7,8-didehydroprotoberberines isolated herein appeared relatively stable, particularly as their trifluoroacetic acid salts. The spatial distributions of the isolated alkaloids were also analyzed using desorption electrospray ionization imaging mass spectrometry. The alkaloids were localized predominantly within the walls and vascular bundles of the capsules, with the highest relative abundances occurring in the lower half of the capsules toward the peduncle. The relative abundances of the alkaloids were also compared across plant development stages. Although most alkaloids did not show clear patterns in their concentration across development stages, the concentration of suspected oxidation products clearly spiked upon plant death. Finally, all isolated natural products were screened for inhibitory activities against a panel of cholinesterases, from both human and animal sources. These studies identified several competitive inhibitors of cholinesterases with potency in the low micromolar range (1–4, 6, 7), offering new lead compounds for the development of cholinesterase inhibitory drugs.